Related Experiment Video

Updated: Jul 9, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Effects of postnatal dexamethasone exposure on the developmental outcome of premature infants

Howard Needelman1, Martha Evans, Holly Roberts

  • 1Munroe-Meyer Institute for Genetics and Rehabilitation, Nebraska Medical Center, Omaha, NE 68198-5440, USA. hneedelm@unmc.edu

Journal of Child Neurology
|December 15, 2007
PubMed

Insights

Extremely low birth weight infants exposed to postnatal dexamethasone showed poorer neurodevelopmental outcomes. This steroid use was a stronger predictor of adverse outcomes than other known risk factors in premature infants.

Area of Science:

  • Neonatal medicine
  • Pediatric neurology
  • Pharmacology

Background:

  • Extremely low birth weight premature infants face significant risks for poor neurodevelopmental outcomes.
  • Postnatal dexamethasone is frequently administered to premature infants to manage bronchopulmonary dysplasia.
  • Concerns exist regarding the potential impact of dexamethasone on infant neurodevelopment.

Purpose of the Study:

  • To retrospectively investigate the effect of postnatal dexamethasone exposure on the early neurodevelopment of extremely low birth weight premature infants.

Main Methods:

  • Retrospective analysis of extremely low birth weight premature infants.
  • Assessment of neurodevelopmental outcomes in relation to postnatal dexamethasone exposure.

Main Results:

  • Dexamethasone exposure was significantly associated with adverse neurodevelopmental outcomes.
  • Steroid exposure emerged as a more potent predictor of outcome compared to established risk factors.

Conclusions:

  • Postnatal dexamethasone use in extremely low birth weight premature infants is linked to poorer neurodevelopmental outcomes.
  • Minimizing the duration of dexamethasone therapy is recommended for these high-risk infants.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...